Modality
Fusion Protein
MOA
SGLT2i
Target
ALK
Pathway
Incretin
RettParkinson'sGBM
Development Pipeline
Preclinical
~Jul 2019
→ ~Oct 2020
Phase 1
Jan 2021
→ Nov 2030
Phase 1Current
NCT08609370
1,271 pts·GBM
2021-01→2030-11·Recruiting
1,271 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-11-184.6y awayInterim· GBM
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1
Recruit…
Catalysts
Interim
2030-11-18 · 4.6y away
GBM
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08609370 | Phase 1 | GBM | Recruiting | 1271 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| Niralucimab | Ionis | Phase 1 | ALK |